Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 23Sarcoma 1

Conditions

Sarcoma 17Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Osteosarcoma 1Neoplasm Metastasis 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gastrointestinal Stromal Tumors 1Desmoid Tumors 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1

Interventions

Gemcitabine 5Docetaxel 4tislelizumab 3Bortezomib 3spartalizumab 2pembrolizumab 2Nivolumab 2Irinotecan 2Filgrastim 2Cisplatin 2Capecitabine 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1tinostamustine 1talazoparib 1surufatinib 1regorafenib 1pazopanib 1pamiparib 1liposomal doxorubicin 1isophosphamide mustard 1futibatinib 1etoposide phosphate 1entinostat 1cc-486 1cabozantinib 1atezolizumab 1anlotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × anlotinib × Sarcoma × Clear all
NCT04165330 2025-02-24

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Sarcoma Oncology Research Center, LLC

Phase 1/2 Active not recruiting
56 enrolled
SarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡